Study guide
1.4 Chronic Disease States and Risk Factors for Critical Illness
Board Certified Critical Care Pharmacist Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pathophysiology and Recognition of Critical Illness
1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness
2 Chapter 2: Medical Devices and Circulatory Support
2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care
3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management
3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation
4 Chapter 4: Vasoactive and Inotropic Therapy in Shock
4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock
5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)
5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness
6 Chapter 6: Cardiovascular Emergencies
6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias
7 Chapter 7: Pulmonary and Infectious Diseases in the ICU
7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU
8 Chapter 8: Neurocritical Care
8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury
9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies
9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy
10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition
10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral
11 Chapter 11: Quality, Safety, and Clinical Guidelines
11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions
12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine
12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management
13 Chapter 13: Treatment Planning and Care Coordination
13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education
1.4 Chronic Disease States and Risk Factors for Critical Illness
Key Takeaways Explain This Topic AI
Chronic comorbidities such as COPD, heart failure, CKD, diabetes, and cirrhosis lower physiologic reserve and accelerate decompensation during acute insult.
Frailty, malnutrition, immunosuppression, and advanced age increase both the risk of ICU admission and the likelihood of poor outcomes.
Medication reconciliation of chronic therapies (beta-blockers, statins, antiplatelets, anticoagulants) is critical because abrupt discontinuation in the ICU precipitates withdrawal events and thrombosis.
The BCCCP blueprint tests whether candidates can integrate chronic disease management into acute resuscitation decisions, including dose adjustments for organ dysfunction and continuation vs. withholding decisions.
Last updated: July 2026
Chronic Disease States and Risk Factors for Critical Illness
Critical illness rarely occurs in a vacuum. Most ICU admissions represent an acute insult layered on chronic disease burden, and the BCCCP Examination Content Outline (1A3, 1A4) explicitly tests the candidate's ability to recognize how chronic conditions modify presentation, complicate pharmacotherapy, and shape prognosis.
High-Prevalence Chronic Disease States in the ICU
Chronic Disease ICU-Specific Implication Pharmacotherapy Consideration
COPD Hypercapnic respiratory failure, beta-agonist and steroid load Avoid non-selective beta-blockers in severe bronchospasm; watch for corticosteroid-induced hyperglycemia
Heart Failure (HFrEF/HFpEF) Volume overload, low cardiac output, cardiorenal syndrome Diuretic resistance, nesiritide, avoidance of negative inotropes in decompensated state
Chronic Kidney Disease Hyperkalemia, uremic platelet dysfunction, fluid overload Renal dose adjustment, avoidance of nephrotoxin stacking, CRRT drug dosing
Diabetes Mellitus DKA/HHS, hyperglycemic crises, hypoglycemia risk Insulin infusion protocols, glucose target 140-180 mg/dL in ICU, avoid sliding scale alone
Cirrhosis Coagulopathy, hepatic encephalopathy, hepatorenal syndrome Albumin for resuscitation, lactulose/rifaximin, avoid nephrotoxic NSAIDs, dose-adjust cleared drugs
Immunosuppression (HIV, transplant, chemo) Opportunistic infection, neutropenic fever Broad-spectrum coverage with antipseudomonal + anti-MRSA + antifungal coverage per risk
Risk Factors for Critical Illness
Non-modifiable: Age >65, male sex, genetic predisposition (e.g., AAT deficiency in COPD, factor V Leiden in VTE), baseline frailty.
Modifiable: Smoking, obesity (BMI >40), alcohol use disorder, sedentary lifestyle, poor medication adherence, uncontrolled chronic disease, lack of vaccination (pneumococcal, influenza, COVID-19).
ICU-acquired risk factors: Nosocomial infection, deep vein thrombosis prophylaxis failure, stress ulcer bleeding, prolonged immobility causing ICUAW, delirium, and post-ICU syndrome.
Chronic Medication Continuity Decisions
The critically ill patient arrives on chronic medications that must be triaged: continue, hold, substitute, or modify dosing.
- Chronic Medication ICU Decision Rationale
- Beta-blockers Continue in most; do not stop abruptly Tachycardia, hypertensive rebound, ischemia
Statins Continue; consider high-dose in sepsis-associated ARDS Pleiotropic anti-inflammatory effects; statin withdrawal increases mortality in sepsis cohorts
- ACE inhibitors/ARBs Hold in septic shock or AKI Risk of AKI, hyperkalemia, hypotension
- Antiplatelets (aspirin, P2Y12) Continue post-PCI; hold for active bleeding Stent thrombosis risk vs. bleeding
- DOACs/warfarin Hold; bridge with heparin if high VTE/stroke risk Half-life prolongation in organ failure
- Insulin Convert to IV insulin infusion in critical illness Subcutaneous absorption unreliable in shock
Levothyroxine Continue; convert to IV (50-70% of PO dose) if GI dysfunction Myxedema coma risk in hypothyroid patients
Integrating Chronic Disease into ICU Triage
The BCCCP candidate must apply chronic disease data to acute decisions. Examples:
COPD patient on home oxygen presenting with pneumonia: lower threshold for non-invasive ventilation, avoid excessive oxygen (CO2 retention), choose antibiotics covering pseudomonas if recent hospitalization.
Cirrhotic with variceal bleeding: early octreotide, ceftriaxone for SBP prophylaxis, albumin-based resuscitation, avoid NSAIDs, watch for hepatorenal syndrome.
Transplant patient on tacrolimus with septic shock: hold tacrolimus during acute kidney injury, check levels, broaden empiric coverage to include MRSA and resistant gram-negatives.
Risk Stratification Tools
APACHE II/IV and SOFA incorporate chronic disease points.
Charlson Comorbidity Index weights comorbidities and predicts 1-year mortality.
Clinical Frailty Scale (CFS) predicts ICU and post-ICU outcomes; CFS >5 is associated with markedly higher mortality.
ICU-acquired weakness (ICUAW) risk rises with prolonged immobility, hyperglycemia, sepsis, and neuromuscular blocker use; early mobility mitigates it.
Medication Reconciliation as a BCCCP Core Skill
The BCCCP Examination Content Outline explicitly tests medication reconciliation (1A4) because the transition into the ICU is a high-risk handoff for chronic therapies. The pharmacist must obtain the best possible medication history (BPMH) from family, outpatient pharmacy fill records, and prior discharge summaries—ICU patients are typically intubated or delirious and cannot self-report. Common reconciliation errors include:
Omission: failing to restart chronic beta-blockers or statins, precipitating withdrawal, stent thrombosis, or statin-withdrawal mortality in sepsis.
Duplication: restarting home carvedilol when a metoprolol infusion is running for atrial fibrillation rate control.
Wrong dose: continuing a home renally cleared antibiotic dose after the patient develops AKI.
Wrong route: continuing subcutaneous insulin in shock when absorption is unreliable.
Reconciliation must be repeated at ICU admission, ICU discharge to stepdown, and hospital discharge, with each transition documented. The BCCCP candidate should be able to construct a one-page reconciliation table listing each home medication, indication, ICU decision (continue/hold/substitute/modify), monitoring plan, and reassessment trigger.
Chronic Disease-Specific ICU Pharmacotherapy Pitfalls
Chronic Disease Pitfall Consequence
COPD on chronic inhaled corticosteroid Systemic steroid underdosing during exacerbation Prolonged mechanical ventilation
Heart failure on sacubitril/valsartan Holding ARNI without substituting ACE inhibitor Worsening heart failure readmission
- CKD on sevelamer or phosphate binders Forgetting to hold during NPO periods Hyperphosphatemia, hypocalcemia
- Cirrhosis on propranolol for portal hypertension Abrupt discontinuation Variceal rebleeding
- Transplant on mycophenolate Holding indefinitely during sepsis Acute rejection risk vs. infection risk balance
- Clinical Scenario
A 72-year-old male with COPD on home oxygen, HFrEF (EF 25%), CKD stage 3, and type 2 diabetes presents with septic shock from pneumonia. His home meds include carvedilol, lisinopril, furosemide, empagliflozin, insulin glargine, and aspirin. Which chronic medications should be held on ICU admission, and what acute adjustments are required?
Answer: Hold lisinopril (hypotension/AKI risk), empagliflozin (euglycemic DKA risk and AKI), and insulin glargine (unreliable subQ absorption in shock; convert to IV insulin infusion targeting glucose 140-180 mg/dL). Continue carvedilol (avoid withdrawal), furosemide (may need IV bolus given anasarca), and aspirin (no active bleeding). Empiric antibiotics should cover Pseudomonas given recent healthcare exposure.